Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Antidepressant or Benzodiazepine or wake-promoting agent

Use the filters below to narrow your results.

generic:
None (2)
brand:
None (10) · Anafranil (1) · Aurorix (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Dalmane (1) · Doral (1) · Edronax (1) · Fetzima (1) · Halcion (1) · Lexotan (1) · Librium (1) · Ludiomil (1) · Marplan (1) · Mogadon (1) · Nardil (1) · Norpramin (1) · Onfi (1) · Parnate (1) · ProSom (1) · Restoril (1) · Rohypnol (1) · Savella (1) · Serax (1) · Serzone (1) · Stablon (1) · Sunosi (1) · Surmontil (1) · Tofranil (1) · Tranxene (1) · Valdoxan (1) · Versed (1) · Vivactil (1) · Wakix (1) · Xanax (1) · Zoloft (1)
classes: (Click arrow to add another value)
mechanism:
None (1) · Extremely potent GABAA positive allosteric modulator (1) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) · GABAA positive allosteric modulator (18) · GABAA positive allosteric modulator; low sedation (1) · GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) · GABAA positive allosteric modulator; very long half-life (1) · Irreversible non-selective MAO inhibitor (3) · Melatonin receptor agonist; 5-HT2C antagonist (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Potent serotonin reuptake inhibitor; also NRI (1) · Reversible inhibitor of MAO-A (1) · Selective dopamine and norepinephrine reuptake inhibitor (DAT and NET inhibition). Unlike amphetamine, does not significantly release monoamines, pure reuptake inhibition. (1) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin reuptake inhibitor and 5-HT2A antagonist (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · Serotonin–norepinephrine reuptake inhibitor (2) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) · Weak SRI; primarily H1/D2/alpha antagonist (1)
uses:
None (40) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · Excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea (OSA) (1) · Excessive daytime sleepiness or cataplexy in adults with narcolepsy (FDA-approved August 2019) (1) · '"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1)
starting dose:
None (40) · 0.25 mg (1) · 25 mg (1) · Narcolepsy: 75 mg PO once daily upon awakening, titrate every 3 days. OSA: 37.5 mg PO once daily, titrate. (1) · Week 1: 8.9 mg PO once daily in the morning. Week 2: 17.8 mg. Week 3+: 35.6 mg (max). Titrate as needed. (1)
preparations:
None (40) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · 4.45 mg, 17.8 mg tablets (1) · 75 mg, 150 mg tablets (1)
fda max:
None (40) · 10 mg/d (1) · 150 mg/d (1) · 200 mg/d (1) · 35.6 mg/d (1)
routes:
None (39) · Oral (5)
onset:
None (39) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) · Wake-promoting effect over weeks of titration (1) · ~30-60 min (1)
duration:
None (39) · 6 h (immediate-release); ~11 h (extended-release) (1) · Chronic daily dosing (1) · Daily morning dosing (1) · Long (1) · ~9 hours (1)
halflife:
None (39) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · ~12 hours (1) · ~20 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) · ~7.1 hours (1)
bioavailability:
None (39) · 80-90% oral (1) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · Not formally established; oral once-daily adequate (1) · ~50% (highly variable) (1) · ~95% (1)
pregnancy:
None (39) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1) · Limited data; pitolisant may reduce hormonal contraceptive efficacy (1) · Limited data; pregnancy exposure registry available (1)
legal:
None (39) · Rx, '''not a controlled substance''' (unique among wake-promoting agents) (1) · Rx, Schedule IV (US) (1) · Rx-only (1) · Rx-only in US (1) · Schedule IV (US) (1)

Showing below up to 44 results in range #1 to #44.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"